<DOC>
	<DOCNO>NCT00821496</DOCNO>
	<brief_summary>This study desgigned look effect multiple dose administration VI-0521 Oral Contraceptive medication .</brief_summary>
	<brief_title>Evaluate Effect VI-0521 Pharmacokinetics Oral Contraceptive Healthy Female Subjects</brief_title>
	<detailed_description>This study design determine multiple oral dos VI-0521 would alter pharmacokinetics oral contraceptive healthy female subject .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>1 . Females , 19 64 year age ( inclusive ) , nonpregnant , plan pregnancy nonbreastfeeding . 2 . If female childbearing potential , use adequate contraception , define double barrier method , single barrier plus tubal ligation . 3 . A body weight least 50 kg body mass index ( BMI ) 27 35 kg/m2 , inclusive . 4 . Medically healthy , clinically insignificant screen result . 5 . Subjects able communicate investigator , understand comply requirement study participation . 6 . Voluntarily consent participate study . 1 . A history presence significant cardiovascular , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic renal disease condition know interfere absorption , distribution , metabolism , excretion drug place subject increase risk determine investigator . 2 . Any clinically significant laboratory abnormality judge investigator . 3 . Any history glaucoma , increase intraocular pressure , medication treat increase intraocular pressure . 4 . Presence cholelithiasis cholecystitis within last 6 month surgically treat cholecystectomy . 5 . Any history cardiovascular cerebrovascular event . 6 . Systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 95 mm Hg screen checkin Day 1 . 7 . Positive urine drug test , serum cotinine test , pregnancy test and/or positive urine alcohol test screen check Day 1 . 8 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) screening . 9 . Any history presence alcoholism drug substance abuse define investigator . 10 . Any active malignancy except basal cell carcinoma . 11 . A history breast cancer . 12 . Any history bipolar disorder psychosis , history psychiatric hospitalization , great one lifetime episode major depression . 13 . A history intolerance oral contraceptive . 14 . A history hypersensitivity idiosyncratic reaction active drug , compound relate study drug excipients present VI0521 capsule . 15 . Use prescription overthecounter ( OTC ) medication , include herbal product , within 14 day prior Day 1 . Up 2 g per day acetaminophen allow discretion Investigator . 16 . Use drug know significance inhibit induce liver enzyme involve drug metabolism [ CYP P450 ] ) within 30 day prior Day 1 . 17 . Blood donation significant blood loss within 56 day prior Day 1 . 18 . Plasma donation within 7 day prior Day 1 . 19 . Any use tobacco nicotine product within 3 month prior Day 1 . 20 . Any history celiac disease , food allergy , vegetarian diet incompatible study objective . 21 . Any subject receive investigational drug within 30 day six halflives , whichever longer , prior dose study . 22 . Clinical judgment investigator subject participate study . 23 . Involvement plan conduct study . 24 . Any subject participate previous clinical trial VI0521 . 25 . Subjects condition possibly affect drug absorption .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Multiple dose administration</keyword>
	<keyword>Oral Contraceptives</keyword>
</DOC>